On August 6, Hong Kong's three major indices showed mixed performance. By midday close, the Hang Seng Index (24,947.57, +45.04, +0.18%) rose 0.18% to 24,947.57 points, while the Hang Seng Tech Index (5,522.74, +1.67, +0.03%) edged up 0.03%. The HSCEI fell 0.03%. Sector-wise, tech stocks were mixed: Alibaba rose over 2%, Tencent and Bilibili gained over 1%, while Meituan and Baidu dropped over 1%. Defense stocks led gains, with CSSC Offshore & Marine Engineering surging over 7%. Apple concept stocks strengthened, with BYD Electronic up over 6%. Coal stocks mostly rose, with China Shenhua advancing over 3%. The innovative drug concept opened higher but closed lower, with Connova Therapeutics falling nearly 5%.

Defense stocks outperformed, with CSSC Offshore & Marine Engineering up over 7%. Shanxi Securities noted that with the launch of the "15th Five-Year Plan" preparations and the approaching 2027 centennial military goal, the defense sector's performance is expected to bottom out in the second half of 2025 and re-enter an upward cycle.

Apple concept stocks gained, with BYD Electronic up over 6%. Internal sources from a German mobile supplier suggest Apple's iPhone 17 series launch is tentatively scheduled for September 9 (early September 10 Beijing time). Earlier, Bloomberg's Mark Gurman predicted Apple would unveil the iPhone 17 in the week of September 8, with September 9 or 10 being the most likely dates. The German carrier's information aligns with Gurman's forecast.

Coal stocks mostly rose, with China Shenhua up over 3%. On August 1, China Shenhua announced plans to issue shares and pay cash to acquire coal, pithead coal power, and coal-to-liquid/coal-to-gas/coal-chemical assets from China Energy Group, along with fundraising. Du Chong, chief coal and transportation analyst at Zhongtai Securities, stated this restructuring would significantly enhance industry concentration and reshape the energy landscape, showcasing an innovative "policy-guided yet market-oriented" approach to supply chain integration with Chinese characteristics.

Innovative drug concept opened high but fell, with Connova down nearly 5%. JPMorgan noted overseas firms are drawn to three core strengths of Chinese assets: robust R&D capabilities for discovering and developing innovative drugs, faster drug development, improved IP protection, and greater recognition from regulators like the FDA and EMA. Quality-driven—rather than price competition—is driving a sector-wide value reassessment.